Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Chisato M. Yamazaki; Aiko Yamaguchi; Yasuaki Anami; Wei Xiong; Yoshihiro Otani; Jangsoon Lee; Naoto T. Ueno; Ningyan Zhang; Zhiqiang An; Kyoji Tsuchikama

doi:10.1038/s41467-021-23793-7

Nature Communications (Jun 2021)

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance

Chisato M. Yamazaki,
Aiko Yamaguchi,
Yasuaki Anami,
Wei Xiong,
Yoshihiro Otani,
Jangsoon Lee,
Naoto T. Ueno,
Ningyan Zhang,
Zhiqiang An,
Kyoji Tsuchikama

Affiliations

Chisato M. Yamazaki: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Aiko Yamaguchi: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Yasuaki Anami: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Wei Xiong: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Yoshihiro Otani: Department of Neurosurgery, The University of Texas Health Science Center at Houston
Jangsoon Lee: Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Naoto T. Ueno: Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center
Ningyan Zhang: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Zhiqiang An: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston
Kyoji Tsuchikama: Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston

DOI: https://doi.org/10.1038/s41467-021-23793-7
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 13

Abstract

Read online

Intratumor heterogeneity in breast cancer can limit the clinical success of antibody-drug conjugates (ADCs). In this study, the authors develop dual payload Her2-ADCs that show potent anti-tumor activity against heterogeneous breast tumors in vivo.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal